Go to deals
Healthcare

Protalix BioTherapeutics, Inc. has completed a private stock placement

Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.

Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Ruben  Eblagon

Ruben Eblagon

Principal

Tel Aviv, Israel
Oaklins Rosario
 Boaz  Levi

Boaz Levi

Partner

Tel Aviv, Israel
Oaklins Rosario
 Olga  Geyber

Olga Geyber

Support

Tel Aviv, Israel
Oaklins Rosario

Related deals

Gilde Healthcare has invested in Tandarts Today
Private Equity | Healthcare

Gilde Healthcare has invested in Tandarts Today

Gilde Healthcare has invested in Tandarts Today, a fast-growing dental chain in the Netherlands. The investment will allow Tandarts Today to accelerate its buy-and-build strategy and become a leading dental chain in the Netherlands. Financial details have not been disclosed.

Learn more
Alcidion (ASX:ALC) has completed a capital raise
Healthcare

Alcidion (ASX:ALC) has completed a capital raise

Alcidion (ASX:ALC) has raised funds to continue its growth strategy.

Learn more
Alcidion (ASX:ALC) has acquired ExtraMed
Healthcare

Alcidion (ASX:ALC) has acquired ExtraMed

Alcidion (ASX:ALC) has acquired ExtraMed Ltd., a UK provider of patient flow management software that helps address key pain-points for hospital administrative staff.

Learn more